Socioeconomic characteristics of patients with coronary heart disease in relation to their cardiovascular risk profile.


Journal

Heart (British Cardiac Society)
ISSN: 1468-201X
Titre abrégé: Heart
Pays: England
ID NLM: 9602087

Informations de publication

Date de publication:
05 2021
Historique:
received: 18 06 2020
revised: 04 09 2020
accepted: 10 09 2020
pubmed: 18 10 2020
medline: 15 12 2021
entrez: 17 10 2020
Statut: ppublish

Résumé

People's socioeconomic status (SES) has a major impact on the risk of atherosclerotic cardiovascular disease (ASCVD) in primary prevention. In patients with existing ASCVD these associations are less documented. Here, we evaluate to what extent SES is still associated with patients' risk profile in secondary prevention. Based on results from a large sample of patients with coronary heart disease from the European Action on Secondary and Primary Prevention through Intervention to Reduce Events study, the relationship between SES and cardiovascular risk was examined. A SES summary score was empirically constructed from the patients' educational level, self-perceived income, living situation and perception of loneliness. Analyses are based on observations in 8261 patients with coronary heart disease from 27 countries. Multivariate logistic regression analyses demonstrate that a low SES is associated (OR, 95% CI) with lifestyles such as smoking in men (1.63, 1.37 to 1.95), physical activity in men (1.51, 1.28 to 1.78) and women (1.77, 1.32 to 2.37) and obesity in men 1.28 (1.11 to 1.49) and women 1.65 (1.30 to 2.10). Patients with a low SES have more raised blood pressure in men (1.24, 1.07 to 1.43) and women (1.31, 1.03 to 1.67), used less statins and were less adherent to them. Cardiac rehabilitation programmes were less advised and attended by patients with a low SES. Access to statins in middle-income countries was suboptimal leaving about 80% of patients not reaching the low-density lipoprotein cholesterol target of <1.8 mmol/L. Patients' socioeconomic level was also strongly associated with markers of well-being. These results illustrate the complexity of the associations between SES, well-being and secondary prevention in patients with ASCVD. They emphasise the need for integrating innovative policies in programmes of cardiac rehabilitation and secondary prevention.

Identifiants

pubmed: 33067329
pii: heartjnl-2020-317549
doi: 10.1136/heartjnl-2020-317549
doi:

Substances chimiques

Cholesterol, LDL 0
Hydroxymethylglutaryl-CoA Reductase Inhibitors 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

799-806

Informations de copyright

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: The authors declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this paper: KK had grant support from the European Society of Cardiology.

Auteurs

Dirk De Bacquer (D)

Department of Public Health and Primary Care, Ghent University, Ghent, Belgium dirk.debacquer@ugent.be.

Inge A T van de Luitgaarden (IAT)

Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

Delphine De Smedt (D)

Department of Public Health and Primary Care, Ghent University, Ghent, Belgium.

Pieter Vynckier (P)

Department of Public Health and Primary Care, Ghent University, Ghent, Belgium.

Jan Bruthans (J)

Centre for Cardiovascular Prevention, First Faculty of Medicine and Thomayer Hospital, Charles University, Prague, Czech Republic.

Zlatko Fras (Z)

Preventive Cardiology Unit, Department of Vascular Medicine, Division of Internal Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia.

Piotr Jankowski (P)

Department of Cardiology, Interventional Electrocardiology and Hypertension, Jagiellonian University Medical College, Kraków, Poland.

Marina Dolzhenko (M)

Shupik's Medical Academy of Postgraduate Education, Kiev, Ukraine.

Kornelia Kotseva (K)

National Institute for Prevention and Cardiovascular Health, National University of Ireland Galway, Galway, Ireland.

David Wood (D)

National Institute for Prevention and Cardiovascular Health, National University of Ireland Galway, Galway, Ireland.

Guy De Backer (G)

Department of Public Health and Primary Care, Ghent University, Ghent, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH